{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-022531","form_type":"8-K","ticker":"AIXC","cik":"0001460702","company_name":"AIxCrypto Holdings, Inc.","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.933811+00:00","generated_at":"2026-06-13T17:00:39.941014+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Qualigen Therapeutics President Amy Broidrick resigns; receives $360K annual severance for 12 months","bullets":["Amy Broidrick resigned as President, Chief Strategy & Operating Officer and director effective June 16, 2023; departure not related to any disagreement.","Separation agreement provides $16,636.79 for accrued salary/vacation and expense reimbursement.","Severance of $360,000 annual salary continued for 12 months post-separation, plus COBRA coverage for 12 months.","Broidrick has three months from separation to exercise vested stock options."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-022531","json":"https://secwatch.observer/filing/0001493152-23-022531.json","markdown":"https://secwatch.observer/filing/0001493152-23-022531.md","text":"https://secwatch.observer/filing/0001493152-23-022531.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223022531/0001493152-23-022531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223022531/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:00:39.941014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c2b017d6c","claim":"Amy Broidrick resigned as President, Chief Strategy and Operating Officer at AIxCrypto Holdings, Inc..","evidence_excerpt":"Amy Broidrick, President, Chief Strategy and Operating Officer and a director of Qualigen Therapeutics, Inc. (the “Company”), provided her resignation to the Company, which became effective June 16, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1460702/000149315223022531/0001493152-23-022531-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President, Chief Strategy and Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}